8d agoStocktwits NewsBEARISH 18Product/PR
Why Is AGIO Stock Falling Today?
The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase 2 trial.
Archived explainer. For the current picture see today's AGIO page.
Why Is AGIOS PHARMACEUTICAL (AGIO) Stock Down Today?
By the Top Tier Newswire AI Desk · July 21, 2026 at 10:41 AM ET · reviewed against 5 wire stories
AGIOS PHARMACEUTICAL (AGIO) is down -4.41% in the latest session. Our newswire has captured 5 stories on AGIO across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 36/100).
AGIO stock is down 4.41% at $38.30 as of the latest trade, driven by the company’s announcement that it will discontinue development of tebapivat for sickle cell disease following Phase 2 trial results. The move has caused a sharp sell-off, with the stock dropping nearly 9% in the first five minutes of trading. The decision comes as Agios continues to advance mitapivat, which is under FDA Priority Review with a PDUFA date set for November 1, 2026.
What Happened
Agios Pharmaceuticals announced it will stop development of tebapivat, an oral pyruvate kinase activator, for sickle cell disease after a 12-week Phase 2 trial involving 59 patients. The firm said the trial results did not meet expectations, leading to the decision to halt further development of the therapy. The announcement was made public through multiple channels, including a trial update and news reports. The stock opened with a -0.9% gap and quickly fell to an intra-day low of $31.12 before stabilizing near $38.30. The move has drawn attention as Agios continues to focus on mitapivat, which is being reviewed for a supplemental New Drug Application.
What The Data Shows
The stock has traded down 5.1% over the past eight sessions, from $42.18 to $40.01. Intraday volume has reached 0.8 million shares, which is 0.7 times the 3-month average. The company has a market cap of $2.2 billion and reported a revenue increase of 78.3% in the trailing twelve months. However, it remains unprofitable with an EPS of -7.25. The stock is currently trading within its 52-week range of $22.24 to $46.00. Recent insider activity includes a $151,000 sale by Chief Medical Officer Sarah Gheuens on July 1. A congressional insider, Rep. Gilbert Cisneros, disclosed a purchase between $1,001 and $15,000 on December 11.
What To Watch
The FDA’s decision on mitapivat, with a PDUFA date of November 1, 2026, will be a key event for the stock. Investors should also monitor coverage breadth and any further updates on the company’s other pipeline developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
AGIO by the numbers
Last: $38.30Session: -4.41%7 sessions: -7.59%Coverage: 5 stories / 5 sourcesAI sentiment: 36/100 (bearish)Mkt cap: $2.2B52w: $22.24 to $46.00
The headlines behind the move
8d agoYahoo FinanceBEARISH 32General
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
8d agoInvestorsHubBEARISH 34Earnings
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) shares fell after the company discontinued development of tebapivat for sickle cell disease following Phase 2 trial results, while continuing to advance mitapivat under FDA Priority Review.
8d agoInvesting.com MarketsBEARISH 34General
Agios Pharmaceuticals stock falls on trial update
Agios Pharmaceuticals stock falls on trial update
8d agoStockTitanBULLISH 63Product/PR
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease | AGIO Stock News
The 12-week study enrolled 59 people with sickle cell disease; mitapivat’s FDA Priority Review carries a Nov. 1, 2026 PDUFA goal date for its sNDA.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AGIO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AGIO move explainers: 2026-07-22 · 2026-07-21